SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is gaining traction, with community members highlighting its availability on Phantom Wallet and relative stability amidst market fluctuations. The crypto is being touted as a potential "moon" candidate, with buyers sharing enthusiasm. Conversations are centered on its performance within the Solana ecosystem.

Moo Deng

MOODENG is trending as traders discuss recent price volatility and potential for a breakout. Community members are debating entry points, with some pointing to technical analysis patterns, while others express skepticism, citing its meme coin status and past performance. The coin's listing on Robinhood and upcoming birthday are also being mentioned as potential catalysts.

Grayscale Bitcoin Mini Trust ETF - Common units of fractional undivided beneficial interest

Grayscale Bitcoin Mini Trust ETF

GBTC is trending as Bitcoin flirts with all-time highs, driving discussion about potential breakouts and future price targets. Community members are closely watching technical indicators and whale activity, anticipating a continued uptrend. Broader market factors, like potential shifts from gold to Bitcoin and the impact of government policies, are also being considered.

The Syndicate Network enables developers to build and operate smart rollups—application-specific blockchains (appchains) with programmable, onchain smart sequencers. Anticipated to launch on September 17, 2025, Syndicate moves sequencing logic from centralized, offchain services into transparent smart contracts on Syndicate Network, allowing applications to customize their transaction ordering, fee structures, and governance models. The SYND token, with a fixed supply of 1 billion tokens, serves as both the native gas token for Syndicate Network and Commons Chain (Syndicate's L3 that settles on Base) and the governance token for the entire network. Originally deployed on Ethereum Mainnet with bridging to Base, SYND launches with 92% of supply minted at genesis and 8% distributed through programmatic emissions over four years. SYND functions as essential infrastructure for network operations and governance. As the gas token, appchain operators use SYND to pay for sequencing transactions, deploying sequencer contracts, and writing blocks to Syndicate Network. As the governance token, SYND holders control the network's direction through a Wyoming Decentralized Unincorporated Nonprofit Association (DUNA), which holds the 258.7 million token treasury. Token holders vote on treasury deployments, network upgrades, and strategic partnerships, ensuring the community maintains control over the ecosystem's evolution. Starting with emissions anticipated October 1, 2025, holders also stake SYND on Commons Chain to earn from an 80 million token pool distributed over 48 thirty-day epochs across three pools: the Base Pool (30%) provides returns proportional to stake amount and duration, the Performance Pool (30%) rewards stakers based on the success of appchains they back, and the Appchain Pool (40%) directly funds appchains based on fees generated and stake attracted. Token holders interact with SYND through standard web3 infrastructure for both staking and governance. After bridging tokens from Ethereum or Base to Commons Chain, holders deposit SYND into the staking contract and allocate their stake across appchains for 30-day epochs. Beginning October 31, 2025, stakers must allocate 100% of their stake to specific appchains, creating direct alignment between token holders and ecosystem growth. Staking rewards are calculated based on both the amount staked and the performance of backed appchains—holders who identify successful appchains early earn outsized returns from the Performance Pool. Beyond staking, token holders participate in governance decisions that shape the network's future, from treasury allocations to protocol upgrades, ensuring the community retains sovereignty over the infrastructure they use. The smart sequencer architecture enables appchains to evolve through smart contract upgrades rather than infrastructure changes—modifying everything from transaction ordering to fee distribution through simple module updates. As the network matures, SYND's role expands to securing Syndicate Network itself through proof-of-stake validation, with the economic model shifting from emission-driven to fee-driven as usage grows. The governance structure ensures that major decisions—from emission schedule adjustments to treasury disbursements for ecosystem development—remain under token holder control through the DUNA framework. This design aligns incentives across all participants: developers capture value through customized appchains, token holders earn returns by backing successful projects while governing the network's direction, and the broader ecosystem benefits from purpose-built chains with programmable economics and atomic cross-chain composability.

Syndicate

Syndax Pharmaceuticals, Inc. engages in the development of cancer therapies. Its products include SyndAccess, Revuforj, Niktimvo, and IncyteCARES. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in New York, NY.

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals is trending following FDA approval of their leukemia drug, Revuforj, though a boxed warning regarding potentially fatal side effects tempers initial enthusiasm. The community is debating the impact of the safety label, comparing it to competitor Kura Oncology's profile, and weighing whether the market is overreacting given the drug's efficacy and the unmet need it addresses. Some believe the dip is a buying opportunity, while others worry about potential risks and side effects.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

ProShares Short Dow30 ($DOG) is trending as community members discuss its potential as a Bitcoin-native meme coin, emphasizing its fair launch and strong community. Some see it as a compelling opportunity within the crypto space, drawing comparisons to other popular meme coins and highlighting its unique position on the Bitcoin network. Community members are actively sharing insights and expressing bullish sentiment, with some anticipating significant growth and exchange listings.

ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in manufacturing, marketing, and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate. The ADMA BioManufacturing segment consists of immune globulin manufacturing and development operations. The Plasma Collection Center consists of source plasma collection facilities. The Corporate segment includes general and administrative overhead expenses. The company was founded by Adam S. Grossman and Jerrold B. Grossman on June 24, 2004 and is headquartered in Ramsey, NJ.

Adma Biologics Inc

ADMA Biologics is trending amid discussions about a potential recall of specific lots and the impact on revenue, with community members analyzing the company's response and comparing it to similar situations with competitors. Some traders are interpreting recent stock sales by the CEO, alongside an FDA safety notice, while others suggest potential manufacturing issues. Despite concerns, many community members express confidence in the company's long-term growth and potential for a buyback.

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU is trending due to growing community engagement and real-world applications, with discussions focusing on its expanding ecosystem and the potential for significant growth. Community members highlight KENDU's unique approach as a permissionless brand, its active IRL presence, and the increasing number of holders. The recent release of a new website is also generating excitement, with many expressing confidence in KENDU's long-term potential.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

TNXP is trending as the stock price continues to drop post FDA approval, leading to discussions around management, dilution, and future prospects. The community is debating whether the current price represents a buying opportunity or reflects deeper issues with the company's leadership and commercialization strategy. Some traders are noting potential short squeeze setups due to high short interest.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference

Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference Anixa Biosciences to Present at the Spartan Capital Securities Second Annual Investor Conference PR...

Are You Looking for a Top Momentum Pick? Why ANIXA BIOSCIENCES INC (ANIX) is a Great Choice

Does ANIXA BIOSCIENCES INC (ANIX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are Medical Stocks Lagging  Amneal Pharmaceuticals (AMRX) This Year?

Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Is Solventum Corporation (SOLV) Stock Outpacing Its Medical Peers This Year?

Here is how Solventum (SOLV) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.

Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and Mind Medicine (MindMed) Inc. (MNMD) have performed compared to their sector so far this year.

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?

Here is how ANIXA BIOSCIENCES INC (ANIX) and CochLear Ltd. Unsponsored ADR (CHEOY) have performed compared to their sector so far this year.

ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy?

Are Medical Stocks Lagging  Anixa Biosciences (ANIX) This Year?

All You Need to Know About Anixa Biosciences (ANIX) Rating Upgrade to Buy

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology and infectious disease. It operates through the following segments: Cancer Vaccines, CAR-T Therapeutics, and Other. The Cancer Vaccines segment includes the early stages development of immunization for breast and ovarian cancer. The CAR-T Therapeutics segment is involved in the development of immuno-therapy drugs against cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA.

Anixa Biosciences Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$3.49
Beta	1.04
Avg. Volume	136,233.14
PE Ratio	-12.01

52-Week High	$4.98
52-Week Low	$2.07
Market Capitalization	$136.28M
EPS (Annual)	-$0.3936
Price to Book	8.19
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

ANIX
Anixa Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ANIX News

ANIXAnixa Biosciences Inc